Introducing CCTG's patient focused trial webpages
Published:Category: Group updates
CCTG is very happy to introduce our patient focused trial webpages that have been developed for recent CCTG trials open to patient enrollment. The goal for this content is to provide CCTG trial specific plain language information for patients and their families that can be used to enhance discussions with their health care team.
Read MorePublications: General Review
Published:Category: Publications
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data
Read MorePublication: Quality of Life study
Published:Category: Publications
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium.
Read MoreTesting early treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Published:Category: Group updates
A unique, patient focused trial aims to explore if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer with a better quality of life if they start treatment earlier. If someone is diagnosed with CLL or SLL they may not have major symptoms and treatment is often started when they show symptoms such as fever, anemia, or night sweats.
Read MoreCCTG NE2 trial successfully funded by CIHR
Published:Category: News
The CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement to support Canadian participation in the STOPNET clinical trial international trial, a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours. Read More
CCTG MY13 receives CIHR funding to study time-limited versus continuous treatment for older people with multiple myeloma
Published:Category: News
The CCTG MY13 study receives $3,056,172 over 8 years to investigate time-limited versus continuous Daratumumab treatment for older people with multiple myeloma.
Read MoreCIHR funding announced for CCTG PR25
Published:Category: News
The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.
Read MoreCIHR has announces funding for the TACtful cell therapy trial
Published:Category: News
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.
Read More